Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Belzutifan |
| Trade Name | Welireg |
| Synonyms | PT2977|MK-6482|PT-2977 |
| Drug Descriptions |
Welireg (belzutifan) is a hypoxia inducible factor-2alpha (EPAS1, HIF2A) inhibitor that suppresses expression of HIF2A target genes, resulting in tumor regression (Mol Cancer Ther 2018,17(1 Suppl):Abstract nr B140, PMID: 31282155). Welireg (belzutifan) is FDA-approved for use in patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that require therapy, in patients with advanced renal cell carcinoma who have received anti-PD-1 or PD-L1 therapy and VEGF inhibitor, in adult and pediatric patients 12 years and older with pheochromocytoma or paraganglioma, and in combination with Keytruda (pembrolizumab) in adult patients with clear cell renal cell carcinoma (FDA.gov). |
| DrugClasses | HIF2A Inhibitor 6 |
| CAS Registry Number | 1672668-24-4 |
| NCIT ID | C135627 |